William Blair Has Negative Outlook for ANRO FY2028 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Equities research analysts at William Blair reduced their FY2028 earnings per share estimates for shares of Alto Neuroscience in a report issued on Tuesday, October 22nd. William Blair analyst M. Minter now expects that the company will post earnings of ($3.26) per share for the year, down from their prior estimate of ($3.16). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.63) per share.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.67) by $0.07.

ANRO has been the subject of a number of other reports. RODMAN&RENSHAW lowered Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Wedbush lowered Alto Neuroscience from an "outperform" rating to a "neutral" rating and decreased their price target for the stock from $29.00 to $4.00 in a research note on Wednesday. Rodman & Renshaw lowered Alto Neuroscience from a "buy" rating to a "neutral" rating in a research note on Wednesday. Finally, Robert W. Baird decreased their price target on Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating for the company in a research note on Wednesday. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $24.40.

Alto Neuroscience Price Performance

Shares of ANRO stock traded up $0.23 on Friday, reaching $4.36. 1,463,434 shares of the company's stock were exchanged, compared to its average volume of 355,474. Alto Neuroscience has a 52 week low of $3.93 and a 52 week high of $24.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.85 and a quick ratio of 19.85. The company's fifty day simple moving average is $12.02 and its 200 day simple moving average is $12.36.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently bought and sold shares of the company. University of Texas Texas AM Investment Managment Co. bought a new position in shares of Alto Neuroscience in the 1st quarter worth $340,000. Jennison Associates LLC bought a new position in shares of Alto Neuroscience in the 1st quarter worth $7,039,000. Vanguard Group Inc. bought a new position in shares of Alto Neuroscience in the 1st quarter worth $8,233,000. Price T Rowe Associates Inc. MD purchased a new position in Alto Neuroscience during the 1st quarter worth $9,788,000. Finally, AWM Investment Company Inc. purchased a new position in Alto Neuroscience during the 1st quarter worth $4,592,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.